Panther Metals Ltd (PNT)
CXA 
Summary
Iridium's PNT ASIC: A New Catalyst Beyond Satellite Connectivity?
IRDM targets the emerging Assured PNT market with its new ASIC, gaining adoption across 150+ organizations and opening recurring revenue opportunities.
Will Adtran's New Oscilloquartz-Assured PNT Solution Drive Top Line?
ADTN's OSA aPNT+ platform delivers robust protection against jamming and spoofing for critical infrastructure and defense sectors.
Panther Metals Ltd (PNT) FAQ
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Panther Metals Ltd ever had a stock split?
Panther Metals Ltd Profile
| Biotechnology Industry | Healthcare Sector | Joe A. McCann CEO | CXA Exchange | US7305411099 ISIN |
| US Country | 129 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
POINT Biopharma Global Inc. is a radiopharmaceutical company focused on the development and commercialization of innovative radioligand therapies aimed at tackling various cancer types. Established in 2019 and headquartered in Indianapolis, Indiana, the company is dedicated to advancing therapeutic options for cancer patients through its leading-edge research and clinical trials. Currently, POINT Biopharma’s two main investigational treatments are in Phase III clinical trials, highlighting the promising potential of its product pipeline in addressing significant medical needs in oncology.
Products and Services
- PNT2002:
PNT2002 is a radioligand specifically engineered to target prostate-specific membrane antigen (PSMA). This treatment is currently undergoing Phase III clinical trials and is being developed to address metastatic castration-resistant prostate cancer, a challenging condition that requires innovative therapeutic strategies. By targeting PSMA, PNT2002 aims to improve patient outcomes and minimize side effects associated with traditional cancer therapies.
- PNT2003:
PNT2003 is a somatostatin-targeted radioligand designed for the treatment of neuroendocrine tumors, currently in Phase III clinical trials. This targeted approach seeks to deliver radiation directly to cancer cells while sparing healthy tissue, potentially offering a more effective and less toxic treatment option for patients suffering from these specialized tumors.
- PNT2001:
PNT2001 is a next-generation PSMA-targeting agent that is currently in preclinical studies. It aims to provide treatment for non-metastatic castration-sensitive prostate cancer. The development of PNT2001 represents POINT Biopharma's commitment to exploring advanced therapeutic avenues to enhance the efficacy of treatment options for earlier-stage patients.
- PNT-2004:
PNT-2004 is directed at fibroblast activation protein-alpha (FAP-a) and is in preclinical development with broad potential across multiple tumor types. This program seeks to address a wide range of cancers by utilizing a novel mechanism of action that targets tumor microenvironments, making it a potentially impactful addition to POINT Biopharma's product suite.
- CanSEEK Technology:
POINT Biopharma is actively involved in developing additional drug candidates using its proprietary CanSEEK technology. This technology has been sub-licensed from Bach Biosciences LLC and Avacta Life Sciences Limited and represents an innovative platform for identifying and delivering targeted cancer therapies effectively. The ongoing exploration of this technology aims to uncover new opportunities in cancer treatment development.
